DBVTechnologies

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
  • TickerDBV
  • ISINFR0010417345
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Jean-Jacques Le Fur

DBV TECHNOLOGIES: Very good results for Viaskin Peanut in the PEOPLE trial | BUY | EUR46(+128%)

DBV TECHNOLOGIES - BUY | EUR46(+128%) Very good results for Viaskin Peanut in the PEOPLE trial An efficacy which appears to increase with time A good safety profile Next catalyst is the Advisory Committee Buy rating reinforced with these results

Jean-Jacques Le Fur

DBV TECHNOLOGIES: Very good results for Viaskin Peanut in the PEOPLE trial | BUY | EUR46(+128%)

DBV TECHNOLOGIES - BUY | EUR46(+128%) Very good results for Viaskin Peanut in the PEOPLE trial An efficacy which appears to increase with time A good safety profile Next catalyst is the Advisory Committee Buy rating reinforced with these results

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior